ALPMY - Astellas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
17.33
-0.01 (-0.09%)
At close: 3:50PM EST
Stock chart is not supported by your current browser
Previous Close17.34
Open17.35
Bid0.00 x 0
Ask0.00 x 0
Day's Range17.30 - 17.39
52 Week Range12.77 - 17.50
Volume21,500
Avg. Volume66,538
Market Cap32.444B
Beta (5Y Monthly)0.82
PE Ratio (TTM)20.29
EPS (TTM)0.85
Earnings DateN/A
Forward Dividend & Yield0.37 (2.13%)
Ex-Dividend DateSep 24, 2019
1y Target EstN/A
  • Astellas Completes Acquisition of Audentes Therapeutics
    PR Newswire

    Astellas Completes Acquisition of Audentes Therapeutics

    Astellas Pharma Inc. (TSE: 4503) (President and Chief Executive Officer: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics, Inc. ("Audentes"), through a tender offer by its indirect wholly-owned subsidiary Asilomar Acquisition Corp. ("Asilomar") for all of the issued and outstanding shares of common stock of Audentes for a price of US$60.00 per share net to the seller in cash ("Tender Offer") and the subsequent merger of Asilomar with and into Audentes. Astellas commenced the Tender Offer on December 16, 2019, New York City time, and the Tender Offer expired at 12:00 midnight, New York City time, at the end of the day on January 14, 2020. As of the expiration of the Tender Offer, 35,852,857 shares of Audentes common stock were validly tendered and not properly withdrawn, representing approximately 76.7% of the shares of Audentes common stock outstanding, and such shares have been accepted for payment under the terms of the Tender Offer. The acquisition positions the combined company to become a global leader in AAV-based genetic medicines.

  • Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline
    Zacks

    Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline

    Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.

  • Benzinga

    The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 26.) Aimmune Therapeutics Inc (NASDAQ: AIMT ...

  • Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
    Reuters

    Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

    Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month. Japan's second biggest drugmaker by sales paid $120 million upfront for Xyphos and the rest will be milestone payments, the companies said in a statement. Astellas also said this month it had agreed to purchase Audentes Therapeutics Inc for about $3 billion to expand its push into genetic medicines.

  • Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
    PR Newswire

    Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Xyphos Biosciences, Inc. (CEO: James Knighton, "Xyphos") today announced that Astellas has acquired Xyphos. With the acquisition Astellas will gain Xyphos' novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as industry-leading immuno-oncology talent, to develop new and potentially better ways to mobilize, target and control immune cells to find, modulate and destroy targeted cells throughout the body.

  • MarketWatch

    Seattle Genetics' stock rises on approval of bladder cancer drug

    The Food and Drug Administration on Wednesday approved Padcev as a treatment for metastatic urothelial cancer. The therapy is jointly being developed by Astellas Pharma Inc. and Seattle Genetics , which began collaborating on this product in 2007. In morning trading on Thursday, Astellas stock was up 0.9% and Seattle's was up 1.25%. The FDA granted the first-in-class drug accelerated approval, based on the EV-201 Phase 2 clinical trial of 125 patients, which reported that 12% of the patients who received Padcev had a complete response to treatment and 32% had a partial response, such as a decrease in tumor size. A confirmatory Phase 3 trial is currently being conducted. Year-to-date, Seattle's stock is up 98%, while shares of Astellas stock have gained 37%. The S&P 500 is up 27%.

  • FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
    PR Newswire

    FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to PADCEV™ for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV is approved under the FDA's Accelerated Approval Program based on tumor response rate. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. PADCEV is the first FDA approved treatment in the U.S. for these patients. It is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,3

  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • MarketWatch

    Pfizer stock ticks higher on new FDA approval for prostate cancer drug

    Pfizer Inc. shares ticked higher in the extended session Monday after the drug maker said the Food and Drug Administration approved a new indication for a cancer drug it makes with Astellas Pharma Inc. . Pfizer shares rose 1.2% after hours, following a 2.1% advance to close the regular session at $39.14. Pfizer said the FDA approved Xtandi to treat patients with metastatic castration-sensitive prostate cancer, or prostate cancer that spreads to other parts of the body and is responsive to treatments that lower testosterone. Xtandi is already approved to treat non-metastatic and metastatic castration-resistant prostate cancer.

  • XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer
    PR Newswire

    XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

    Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). In 2019, it is estimated that just over 40,000 men in the United States are living with mCSPC, a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone.1,2,3

  • Moody's

    Astellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade

    Moody's Japan K.K. has placed Astellas Pharma Inc.'s A1 issuer ratings under review for downgrade. The rating action follows Astellas' announcement on 3 December 2019 that it had entered into a definitive agreement to acquire the entire stock of Audentes Therapeutics, Inc. for approximately USD3 billion. "This acquisition indicates an urgency for Astellas to feed its long term product pipeline after a wave of patent expiries this year, and signals a rise in acquisition event risk," says Akifumi Fukushi, a Moody's Vice President and Senior Analyst.

  • GuruFocus.com

    Astellas-Audentes Deal Likely to Ignite More Acquisitions

    Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios Continue reading...

  • Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science
    PR Newswire

    Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science

    Astellas Venture Management (President: Shunichiro Matsumoto, Ph.D., MBA, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), and Mission Bay Capital BioLabs ("MBC BioLabs"), a life-science incubator, today announced AmbAgon Therapeutics and Gordian Biotechnology as the winners of the Astellas-sponsored "Golden Ticket Competition." The award supports advancing early-stage companies' pre-clinical scientific discoveries, reflecting Astellas' ongoing commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide.

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.
    PR Newswire

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc.

    WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Audentes Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ: BOLD) in connection with the proposed acquisition of the Company by Astellas Pharma Inc. ("Astellas Pharma") (OTC:ALPMY). Under the terms of the acquisition agreement, BOLD shareholders will receive $60.00 per share in cash.

  • This Gene Therapy Stock Just Netted A $3 Billion Bid — Who's Next?
    Investor's Business Daily

    This Gene Therapy Stock Just Netted A $3 Billion Bid — Who's Next?

    Shares of Audentes Therapeutics rocketed more than 100% Tuesday on news Japanese pharmaceutical company Astellas Pharma will acquire the gene therapy biotech company for $3 billion.

  • Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition
    MarketWatch

    Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition

    Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020.

  • Benzinga

    Japan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash

    Astellas and Audentes Therapeutics Inc (NASDAQ: BOLD) said they have entered a definitive agreement for the former to acquire the latter for $60 per share in cash, representing a total equity value of about $3 billion. The per-share transaction value represents a 110% premium to Audentes' Monday closing price of $28.61. Astellas, through Asilomar, an acquisition vehicle of its U.S. subsidiary, will commence in the next few weeks a tender offer to buy all outstanding Audentes shares.

  • Barrons.com

    Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals.

    Astellas Pharma is paying $60 a share in cash for a gene-therapy stock that closed at $28.61 on Monday.

  • MarketWatch

    Astellas bets $3 billion in gene therapy deal

    Shares of Astellas Pharma Inc. rose about 1% in premarket trading after the Japanese drugmaker said Monday evening that it plans to acquire Audentes Therapeutics for $3 billion in cash. Audentes is developing gene therapies. Its stock jumped 105% in premarket trading. "This is just another bullish domino for genetic medicine," Raymond James' Steven Seedhouse wrote in a research note. In recent years, there have been a number of high-profile buyouts of companies developing gene therapies, including Roche's $4.8 billion pending acquisition of Spark Therapeutics and Novartis's $8.7 billion purchase of AveXis. Astellas said the boards of both companies have approved the deal. Shares of Astellas have gained 35% year-to-date, while the S&P 500 is up about 24%.

  • Benzinga

    The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...

  • TheStreet.com

    [video]Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase

    Astellas Pharma says it's going to buy the clinical stage biotech company for $3 billion in cash.

  • Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
    PR Newswire

    Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new data in acute myeloid leukemia (AML) at the 61st American Society of Hematology (ASH) Annual Meeting, taking place Dec. 7-10 in Orlando, Fla.

  • Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
    PR Newswire

    Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

    Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate (ADC) enfortumab vedotin and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with previously untreated metastatic urothelial cancer.

  • Benzinga

    The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...